Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer

Journal of Clinical Oncology, 04/18/2012

Interval to biochemical failure (IBF) is the single most robust prognostic factor for prostate cancer mortality (PCM) following radiotherapy (RT) without androgen deprivation therapy. This external validation demonstrates that patients and clinicians can use this information to make decisions about subsequent treatments.

Print Article Summary Cat 2 CME Report